Identifing novel therapeutic target molecules in multiple myeloma using BCL9-ChIPSeq
Project/Area Number |
25461430
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Hematology
|
Research Institution | Sapporo Medical University |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
KAMIHARA YUSUKE 札幌医科大学, 医学部, 研究員 (10624421)
KATO JUNJI 札幌医科大学, 医学部, 教授 (20244345)
KOBUNE MASAYOSHI 札幌医科大学, 医学部, 准教授 (90336389)
|
Project Period (FY) |
2013-04-01 – 2016-03-31
|
Project Status |
Completed (Fiscal Year 2015)
|
Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
|
Keywords | BCL9 / 多発性骨髄腫 |
Outline of Final Research Achievements |
Multiple myeloma (MM) is characterized by clonal proliferation of long-lived plasma cells within the bone marrow. Despite recent advances in its treatment, MM remains an incurable disease, underlining the need to continue exploring its molecular characteristics. We have identified that BCL9 has a pivotal role in MM pathogenesis. In this study, we found that CYBRD1, which is a iron regulating molecule, as a novel therapeutic target in MM using BCL9-Chromatin Immunoprecipitation (ChIP)-Sequence (Seq) (ChIPSeq).
|
Report
(4 results)
Research Products
(24 results)
-
-
-
-
[Journal Article] Effect of duloxetine in Japanese patients with chemotherapy-induced peripheral neuropathy: a pilot randomized trial.2015
Author(s)
Hirayama Y, Ishitani K, Sato Y, Iyama S, Takada K, Murase K, Kuroda H, Nagamachi Y, Konuma Y, Fujimi A, Sagawa T, Ono K, Horiguchi H, Terui T, Koike K, Kusakabe T, Sato T, Takimoto R, Kobune M, Kato J
-
Journal Title
Int J Clin Oncol
Volume: 20
Issue: 5
Pages: 866-871
DOI
Related Report
Peer Reviewed
-
-
-
[Journal Article] A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer.2015
Author(s)
Sato Y, Ohnuma H, Hirakawa M, Takahashi M, Osuga T, Okagawa Y, Murase K, Takada K, Kawano Y, Iyama S, Hayashi T, Sato T, Miyanishi K, Takimoto R, Kobune M, Okita K, Mizuguchi T, Furuhata T, Hirata K, Kato J
-
Journal Title
Cancer Chemother Pharmacol
Volume: 75
Issue: 3
Pages: 587-597
DOI
Related Report
Peer Reviewed / Open Access
-
-
-
[Journal Article] Efficacy of Enteral Supplementation Enriched with Glutamine, Fiber, and Oligosaccharide on Mucosal Injury following Hematopoietic Stem Cell Transplantation2014
Author(s)
Iyama S, Sato T, Tatsumi H, Hashimoto A, Tatekoshi A, Kamihara Y, Horiguchi H, Ibata S, Ono K, Murase K, Takada K, Sato Y, Hayashi T, Miyanishi K, Akizuki E, Nobuoka T, Mizuguchi T, Takimoto R, Kobune M, Hirata K, Kato J.
-
Journal Title
Case Rep Oncol
Volume: 7
Issue: 3
Pages: 692-699
DOI
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant
-
-
-
-
-
-
-
-
-
-
-
-
-
-